PharmaMar is closer to have another cancer drug on the market, after the success of phase III trials with Aplidin for Multiple Myeloma.
Based in Madrid, PharmaMar is a Biopharma developing anti-cancer drugs, with an interesting strategy for drug discovery. It researches compounds present in marine organisms and assess if they have any biological action on tumor cells.
This kind of bio-mining is being done in many environments – including deserts. For PharmaMar, it yielded 4 potential candidates so far – one of which (Yondelis) is already on the market for soft tissue sarcomas and ovarian cancer.
Now, the company is preparing to submit a second drug Aplidin (plitidepsin) for market authorization with the EMA, the compound of which was obtained from the Sea squirt Aplidium albicans – a sac-like marine invertebrate.